Why Patent Data Is the Most Underused BD Tool in CDMO Sales Most CDMOs sell on the same four claims: […]

Global Key Takeaways The FDA’s Orange Book is not a passive regulatory registry. It is the legal terrain on which

Executive Summary: The Economics of Loss of Exclusivity In the pharmaceutical sector, the transition from patent exclusivity to generic or

A single ClinicalTrials.gov entry can redirect millions in legal fees. When a specialty pharma company quietly posts a Phase II

The global generic pharmaceutical industry is undergoing a technical overhaul. In 2024, the contract manufacturing market for generics reached a

Why Patent Challenges Move Markets A single successful Paragraph IV challenge on a blockbuster drug can redirect $2-5 billion in

I. Drug Patent Status as a Financial Variable, Not a Legal Footnote The Misread Signal Most analysts treat drug patent

Pharmaceutical companies collectively lose an estimated $250 billion in annual revenue to patent cliffs, regulatory missteps, and compliance failures that

When a pharmaceutical patent expires, it does not quietly fade. It detonates. Revenue can collapse by 80 to 90 percent